Maretchia Ghattas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maretchia Ghattas has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Anselmo J. Otero-Gonzalez
Center for Protein Studies, Faculty of Biology, University of Havana, 25 and I, La Habana 10400, Cuba
1 shared publication - Armando Rodriguez
ULMTeC Core Facility for Functional Peptidomics, Ulm University Medical Center, 89081 Ulm, Germany
1 shared publication - Ludger Ständker
Core Facility for Functional Peptidomics (CFP), Faculty of Medicine, Ulm University, 89081 Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 3 October 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (10) , 1381
Discovery, Optimization, and Clinical Application of Natural Antimicrobial Peptides
Antimicrobial peptides (AMPs) are widespread in multicellular organisms. These structurally diverse molecules are produced as the first line of defense against pathogens such as bacteria, viruses, fungi, and parasites. Also known as host defense peptides in higher eukaryotic organisms, AMPs display immunomodulatory and anticancer activities. During the last 30 years, technological advances have boosted the research on antimicrobial peptides, which have also attracted great interest as an alternative to tackling the antimicrobial resistance scenario mainly provoked by some bacterial and fungal pathogens. However, the introduction of natural AMPs in clinical trials faces challenges such as proteolytic digestion, short half-lives, and cytotoxicity upon systemic and oral application. Therefore, some strategies have been implemented to improve the properties of AMPs aiming to be used as effective therapeutic agents. In the present review, we summarize the discovery path of AMPs, focusing on preclinical development, recent advances in chemical optimization and peptide delivery systems, and their introduction into the market.
- 3 October 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (10) , 1381
Open AccessDiscovery, Optimization, and Clinical Application of Natural Antimicrobial Peptides
Antimicrobial peptides (AMPs) are widespread in multicellular organisms. These structurally diverse molecules are produced as the first line of defense against pathogens such as bacteria, viruses, fungi, and parasites. Also known as host defense peptides in higher eukaryotic organisms, AMPs display immunomodulatory and anticancer activities. During the last 30 years, technological advances have boosted the research on antimicrobial peptides, which have also attracted great interest as an alternative to tackling the antimicrobial resistance scenario mainly provoked by some bacterial and fungal pathogens. However, the introduction of natural AMPs in clinical trials faces challenges such as proteolytic digestion, short half-lives, and cytotoxicity upon systemic and oral application. Therefore, some strategies have been implemented to improve the properties of AMPs aiming to be used as effective therapeutic agents. In the present review, we summarize the discovery path of AMPs, focusing on preclinical development, recent advances in chemical optimization and peptide delivery systems, and their introduction into the market.